A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
HI-RTE allows the assessment and real-time colour display of tissue elasticity. The current generation ultrasound modality has proven applications in breast, prostate, thyroid and pancreatic disease and where diagnostic biopsy is indicated, HI-RTE allows more accurate localization and targeting of lesions.
During the IFCC and EuroMedLab congress in Berlin, Beckmann Coulter launched into Europe its AU 5800, which, the firm reports, improves processing time compared to current systems and therefore meets the demands of ever faster workflow in clinical laboratories.
The role of prostate-specific antigen (PSA) in prostate cancer detection continued to command attention at during the annual congress of the European Association of Urology (EAU) in March.
Prostate cancer is the most frequently diagnosed cancer in males in developed countries and the sixth leading cause of cancer death worldwide. One reason for the increase in diagnosis is the widespread uptake of the prostate-specific antigen (PSA) test, capable of detecting slow growing cancers that might otherwise go undetected.
In 2005, when they founded the French ultrasound company SuperSonic Imagine, Jacques Souquet PhD and Claude Cohen-Bacrie had to convince radiologists that they not only offered a new product but also a completely new ultrasound technology that could measure entirely new parameters.
As one of the most advanced forms of precision radiotherapy, proton therapy enables the irradiation of tumours located deep within the body, in the proximity of critical organs, such as the optic nerve or some brain areas. The Institut Curie has renovated its proton therapy centre in Orsay near Paris. Since 1991, when the original centre opened, it has treated over 5,000 patients (4,000 for eye…
There will be nearly 1.3 million deaths from cancer in Europe in 2011 according to predictions from a study published in the cancer journal, Annals of Oncology. The estimates, which have been reached after researchers used for the first time in Europe a new mathematical model for predicting cancer mortality, show a fall in overall cancer death rates for both men and women when compared to 2007.
Scientists from the Cancer Research UK Cambridge Research Institute and The Institute of Cancer Research (ICR) built on earlier genome-wide research to link a genetic change associated with prostate cancer risk to a significant reduction in the amount of a protein called microseminoprotein-beta (MSMB). The protein - which regulates prostate cell death - is produced by normal prostate cells –…
The European Association of Urology (EAU), the European knowledge centre of urology, and the national urological societies in Europe organise Urology Week annually – this year from 13 to 17 September - to inform people, especially men over 50, about urological diseases, their treatments and the work of the urologist.
The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality was given a boost in 2009 when the conclusive findings from the 10-year European Randomized Study of Screening for Prostate Cancer (ERSPC) -- the world’s largest prostate cancer screening study – were published.
The European Association of Urology reiterated that it does not recommend a mass screening policy in Europe for men who are concerned over prostate cancer, a stance which reflects the position it issued last year regarding prostate cancer screening.
New research on deaths from cancer in Europe concludes that the key priority for continuing to reduce mortality is cutting tobacco smoking. The study shows that, while deaths for men from lung cancer in the EU have declined overall, by 17 % from 1995 to 2004, they rose by 27% for women over the same period. It also reveals other significant differences in the mortality between different EU…
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer tremendously from the stressful treatment which can be harmful to the developing brain. Therefore, there is an urgent need for target-oriented, gentle treatment methods. The most important childhood brain tumors are medulloblastoma, which is diagnosed in approximately one…
French expert Dr Jacques Souquet PhD, President of SuperSonic Imagine, describes the value and potential of ShearWave elastography, the latest development in ultrasound that enables radiologists to acquire user independent information about tissue stiffness by measuring both, ultrasound and shear waves.
Professor Roger Tsien, Nobel Laureate in Chemistry 2008 for the ‘Discovery and Development of Green Fluorescent Proteins’, was one three* Keynote Speakers at the opening ceremony of the Medical Physics and Bioengineering World Congress 2009, held in Munich this September.
Pain is the most common symptom of any illness thus having an alerting function to evoke protective responses. If tissue damage has happened as a consequence of surgery, obstruction, injuries, or cancer a cascade of changes in the peripheral and central nervous system occurs leading to physical inactivation, an increase of morbidity thus delaying hospital stay and treatment costs.
According to a major recent study, appearing in the July 27 issue of the "Journal of Clinical Oncology," there is a definite downstaging trend for prostate cancer. The study, which surveyed almost 13,000 American men who had a radical prostatectomy (surgical removal of a cancerous prostate gland) between 1987 and 2005, found that only 12% of them died of the cancer. This is great news, according…
The first joint congress ECCO 15 - ESMO 34 of the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) is taking place this week in Berlin. It is the only congress in Europe that covers the entire spectrum of cancer from basic science and translational research, to prevention, treatment, nursing and supportive care for all types of tumours.
A new initiative designed to inform and educate policymakers at national, European, and global level about the needs of the oncology community was launched at Europe's largest cancer congress, ECCO 15 — ESMO 34, in Berlin. The European Academy of Cancer Sciences will help to keep the interests of cancer patients at the forefront of the policy agenda, and avoid policy decisions that had a…
During a gathering of clinicians, scientists and economists at this year's Medical Technology Congress (Treffpunkt für Medizintechnik) held in Berlin's Charité Hospital, all 17 lectures focused on cancer treatments. Bettina Döbereiner reports
Barcelona, Spain 26-29 November
Dresden, Germany 16-19 September
Completion of a Phase I clinical trial has demonstrated the great promise of a completely new type of cancer treatment, according to results announced this June in The New England Journal of Medicine by scientists at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in the United Kingdom, working with pharma firm AstraZeneca.
Positive CB7630 (Abiraterone Acetate) Phase II Data was presented at the ASCO Annual Meeting in Chicago this May/June, Cougar Biotechnology Inc, a development stage biopharmaceutical firm with a specific focus on oncology. In mid-July, Johnson & Johnson announced its acquisition of Cougar, which is now working with Ortho Biotech Oncology Research & Development, a division of the J&J firm Centocor…